Adagene at H.C. Wainwright conference: higher-dose CTLA-4 push

Adagene reported confirmed response rates of 15%-36% and median overall survival of about 20 months for ADG126 plus pembrolizumab in late-line microsatellite-stable colorectal cancer patients without liver metastases, compared with roughly 0%-3% response rates for historical PD-1 or CTLA-4 regimens. Its randomized Phase II Project Optimus trial is testing 10 mg/kg every three weeks versus 20 mg/kg every six weeks, with primary data expected in H1 2027; a Phase III could start in 2027 subject to results and an FDA end-of-Phase-II meeting. The masked CTLA-4 candidate showed discontinuation from adverse events below 10%, though Grade 3 adverse events rose from about 15% at 10 mg/kg to about 30% at 20 mg/kg. Adagene raised $70 million in April 2025 and is pursuing partnerships and non-dilutive funding, but the investment case remains dependent on forthcoming clinical validation and regulatory alignment.

Analysis

ADAG’s valuation hinges on whether its apparent therapeutic-index advantage survives randomized testing, not on the ability to administer a nominally higher dose. The key hidden risk is enrichment: excluding liver-metastatic disease selects a biologically distinct, less immunosuppressive colorectal population, so early efficacy may not translate into the broader registrational population. Small cohorts also make adverse-event discontinuation a weak safety proxy; grade-3 toxicity, steroid use, treatment delays, and exposure-adjusted toxicity will matter more to FDA and commercial adoption than headline discontinuation rates.

The next meaningful repricing catalyst is 1H27 randomized Phase II data, leaving little fundamental reason for sustained upside over the next 3-6 months absent a financed partnership or external combination data. A positive result must show not merely response replication but durable PFS separation and a usable dose schedule; otherwise the company faces a longer, expensive OS-driven pivotal path and likely equity dilution before value inflection. The undisclosed cash runway is material: a healthy current ratio does not establish funding capacity for a global Phase III program.

INCY and SNY gain inexpensive optionality if ADG126 improves outcomes in their respective combination programs, but neither collaboration is likely large enough to alter near-term estimates without a formal economic expansion. The more important competitive read-through is negative for first-generation CTLA-4 franchises only if masked CTLA-4 demonstrates reproducible efficacy with clearly lower immune-mediated toxicity; AZN’s existing combination experience sets a high evidentiary bar. Consensus may be over-crediting the platform’s breadth before one randomized proof point establishes that tumor-local activation is clinically meaningful rather than pharmacologically elegant.

Key Decisions for Investors

• Maintain ADAG as watchlist/event-driven only; do not establish a core long before randomized Phase II enrollment progress, cash runway disclosure, and 1H27 data. The stock can rally on partnership headlines, but the fundamental catalyst is too distant relative to financing and execution risk.
• For biotech-event capital, consider a small ADAG starter only after confirming at least 18 months of runway and stable Phase II enrollment; cap exposure at binary-event sizing. Add only if randomized data show at least mid-teens confirmed ORR with durable PFS and no material increase in grade-3 immune toxicity versus the lower-dose arm.
• Use INCY as the cleaner liquid read-through rather than chasing ADAG on conference commentary: maintain a modest long bias only if its PD-1/TGF-beta program produces liver-metastatic CRC activity in combination. Falsifier: no incremental efficacy over INCY’s monotherapy benchmark or safety that prevents adequate exposure.
• Avoid shorting AZN solely on this thesis. A competitive displacement case requires randomized ADG126 evidence across a broader population and would be a 12-24 month issue; AZN’s diversified oncology earnings are not meaningfully sensitive to an early-stage competitor today.
• Set alerts for FDA end-of-Phase-II feedback and any equity raise. A Phase III design requiring OS as the sole primary endpoint, or a financing before a value-creating partnership, would increase dilution-adjusted downside and invalidate a pre-data long thesis.